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Abstract 
Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in the prostanoid biosynthesis 
pathway, converting arachidonic acid into prostaglandin H2.  COX-2 exists as 72 and 74 kDa glycoforms, 
the latter resulting from an additional oligosaccharide chain at residue Asn580.  In this study, Asn580 was 
mutated to determine the biological significance of this variable glycosylation.  COS-1 cells transfected 
with the mutant gene were unable to express the 74 kDa glycoform and were found to accumulate more 
COX-2 protein and have five times greater COX-2 activity than cells expressing both glycoforms.  Thus, 
COX-2 turnover appears to depend upon glycosylation of the 72 kDa glycoform. 
 
Keywords: cyclooxygenase-2; post-translational regulation; enzyme turnover; glycosylation; glycoforms; 
site-directed mutagenesis  
 
Abbreviations: COX, cyclooxygenase; AA, arachidonic acid; PGG2, prostaglandin G2; PGH2, 
prostaglandin H2; kDa, kilodalton; DMEM, Dulbecco’s Modified Eagle’s Medium; FBS, fetal bovine 
serum; PBS, phosphate buffered saline; SDS, sodium dodecyl sulfate; ELISA, enzyme-linked 
immunosorbent assay; OA, octanoic acid; PGE2, prostaglandin E2; PI3K, phosphatidylinositol 3-kinase; 
NSAIDs, nonsteroidal anti-inflammatory drugs; ER, endoplasmic reticulum 
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1. Introduction 
Prostanoids, which consist of prostaglandins and thromboxanes, represent a family of lipid-
soluble, bioactive compounds which have been associated with a multitude of physiological processes and 
pathophysiological conditions that include: platelet aggregation, bone metabolism, ovulation, 
inflammation, ischemia, and various cancers (reviewed in [1]).  The rate-limiting step in the prostanoid 
synthesis pathway is catalyzed by the integral membrane protein cyclooxygenase (COX), also known as 
prostaglandin H2 synthase [2,3], which is localized to the endoplasmic reticulum (ER) and nuclear 
envelope [4].  COX is bifunctional, converting arachidonic acid (AA), an omega-6 fatty acid, to the 
precursor prostaglandin G2 (PGG2) and subsequently converting PGG2 to the precursor prostaglandin H2 
(PGH2) via cyclooxygenase and peroxidase activities, respectively.  Three isoforms of COX have been 
found— the constitutively expressed COX-1 [5-7]; COX-2, which can be inducible or constitutive, 
depending on the tissue [1,8-10]; and the constitutively expressed COX-3, which is believed to be a splice 
variant of COX-1 [11].  Although COX-1 is considered the housekeeping enzyme expressed in nearly all 
tissues, COX-2 is generally perceived to be involved in pathological conditions, such as inflammation and 
cancer [1,12,13].  In particular, we have found that the presence of AA in human prostate cancer cells up-
regulates COX-2 mRNA and protein expression [14,15]— specifically, the 72 kDa glycoform [16].  
However, COX-2 is also involved with normal physiological processes such as neurotransmission and 
synaptic activity [17,18], maintaining normal renal functions [19], providing vascular protection [20], 
regulating cerebral blood flow [21], and facilitating pregnancy [22].   
The COX-2 sequence contains five potential N-glycosylation sites, three of which are always 
glycosylated, one (Asn580 in human and mouse) that is glycosylated ≤ 50% of the time, and one that is 
never glycosylated [23].  The carbohydrate moieties at each site are believed to be high-mannose chains 
[24,25].  The variability of glycosylation at Asn580 leads to the production of two distinct glycoforms of 
72 and 74 kDa.  Previous studies have examined this variable glycosylation at the Asn580 site, but none 
were able to determine the purpose or biological significance of the two COX-2 glycoforms [23,25]. 
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In this study, we strove to determine the purpose of glycosylation at Asn580— specifically, if and 
how this additional glycosylation affects COX-2 activity.  We found that glycosylation at Asn580 does 
indeed affect total COX-2 activity by controlling the enzyme’s turnover.   
 
2. Materials and methods 
2.1. Materials 
The human COX-2 cDNA in plasmid pcDNA3 was generously provided by Dr. Timothy Hla 
from the University of Connecticut, USA.  The COS-1 cell line was obtained from the UCSF Cell Culture 
Facility (San Francisco, CA, USA).  QIAprep Spin Miniprep kit, HiSpeed Plasmid Maxi kit, and the 
primers used for site-directed mutagenesis (5'-
TCATTAAAACAGTCACCATCCAGGCAAGTTCTTCCCGCTC-3' and 5'-
GAGCGGGAAGAACTTGCCTGGATGGTGACTGTTTTAATGA-3') were purchased from QIAGEN 
(Valencia, CA, USA).  The PfuUltra HF DNA polymerase was purchased from Stratagene (La Jolla, CA, 
USA).  The transfection reagent FuGENE 6 was purchased from Roche Applied Science (Indianapolis, 
IN, USA).  One Shot TOP10 Competent E. coli cells, pre-made 4%- 12% Bis-Tris NuPAGE gels, and the 
NuPAGE system were obtained from Invitrogen (Carlsbad, CA, USA).  The anti-human COX-2 
polyclonal antibody, the Prostaglandin E2 EIA kit—Monoclonal and peroxide-free arachidonic acid were 
purchased from Cayman Chemical (Ann Arbor, MI, USA).  Octanoic acid was purchased from Sigma.   
 
2.2. Site-directed mutagenesis  
DNA primers were designed to convert the Asn residue at site 580 in the human COX-2 sequence 
to a Gln residue.  The mutagenesis reaction contained pcDNA3-COX-2, sense and antisense DNA 
primers, dNTP mix, and PfuUltra HF DNA polymerase.  The reaction was incubated at 95°C for 30 
seconds.  This was followed by 16 cycles of:  95°C for 30 seconds, 55°C for 1 minute, and 68°C for 7 
minutes, 30 seconds.  The restriction enzyme DpnI was then added to the reaction to cleave up the 
original plasmid, leaving intact only plasmids containing the mutant COX-2 gene.   
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2.3. Transfection of COS-1 cells  
One Shot TOP10 Competent E. coli cells were used to produce large quantities of plasmid 
containing either the wild-type or mutant COX-2 gene.  Plasmids were isolated and purified using the 
HiSpeed Plasmid Maxi kit according to the manufacturer’s instructions.  COS-1 cells were grown on 6-
well plates in DMEM, 1% FBS media at 37°C.  FuGENE 6 reagent was used to transiently transfect cells 
with either the wild-type or mutant COX-2 gene according to the manufacturer’s instructions.  Cells were 
incubated at 37°C for 4- 5 hours in the presence of the FuGENE 6/COX-2 DNA complex.  Media was 
replaced with DMEM, 10% FBS, 4 mM L-glutamine, and antibiotics, and the cells continued their 
incubation.   
 
2.4. Western blot analyses 
Transfected and nontransfected COS-1 cells growing on 6-well plates were washed with ice-cold 
PBS and then lysed.  The whole cell lysates were sonicated briefly and subjected to centrifugation at 
14,000x g for 5 minutes to remove cytoskeletal structures.  Protein concentrations were determined, and 
cell lysate samples underwent gel electrophoresis using either 4%- 12% Bis-Tris NuPAGE gels or 16 cm, 
7% SDS-polyacrylamide gels.  After electrophoresis, proteins were transferred to nitrocellulose and 
immunostained for COX-2 protein using anti-human COX-2 polyclonal antibody.  The membrane was 
also immunostained for the housekeeping gene β-actin.  Bound antibody was detected using 
chemiluminescence and film.  Densitometry analyses were then carried out using the software UNSCAN-
IT by Silk Scientific. 
 
2.5. ELISA for measuring PGE2 levels  
Transfected and nontransfected COS-1 cells growing on 6-well plates were treated with 5 µg/ml 
of either AA or OA for 2 hours at 37 °C, as previously described [16].  Media samples were then 
collected and analyzed for the presence of the downstream product prostaglandin E2 using a 
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Prostaglandin E2 EIA kit—Monoclonal.  Dilutions of the media samples were prepared in a 96-well plate 
and were treated and analyzed according to the manufacturer’s instructions.    
 
2.6. Statistical analysis  
Using Instat 3 software, densitometry data were subjected to One-way Analysis of Variance 
(ANOVA).  ELISA results were also subjected to ANOVA followed by the Student-Newman-Keuls 
Multiple Comparisons Test. 
 
3. Results and discussion 
3.1. Mutagenesis of glycosylation site Asn580 affects glycoform expression 
By replacing asparagine (Asn) with glutamine (Gln) at residue 580 of the human COX-2 gene, we 
effectively eliminated glycosylation at that site (Fig. 1A).  As a result, COS-1 cells transfected with the 
mutant gene were able to express the 72 but not the 74 kDa glycoform found in cells expressing the wild-
type gene.  The mutation also resulted in the expression of a “new” 70 kDa glycoform, but the mechanism 
behind its formation is as yet unknown.  Fig. 1A shows a significantly large accumulation of both the 70 
and the 72 kDa proteins.  In short, removal of the glycosylation site appeared to increase total COX-2 
protein levels.  To confirm this, a timecourse experiment was conducted in which expression patterns of 
the glycoforms were analyzed 3, 4, and 5 days after transient transfection with either the wild-type or 
mutant COX-2 gene (Fig. 1B).  The concentrations of the two glycoforms expressed from the mutant gene 
continued to be greater than those expressed from the wild-type gene, even as total COX-2 expression 
started to wane by Day 5.  This verified that removal of the Asn580 glycosylation site slowed down the 
turnover of the COX-2 protein. 
 
3.2. Effect of glycosylation on total COX-2 activity 
To determine if the accumulation of COX-2 in cells expressing the mutant gene also resulted in 
an increase in total COX-2 activity, levels of the downstream end-product prostaglandin E2 (PGE2) were 
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measured (Fig. 2).  Cells carrying either the wild-type (WT) or mutant (MUT) COX-2 gene were treated 
with the COX-2 substrate AA for 2 hours.  PGE2, released by cells into the media, was measured using an 
ELISA.  As Fig. 2 shows, AA-treated cells expressing the 70/ 72 kDa glycoforms had the greatest PGE2 
levels— five times greater than the levels found in AA-treated cells expressing the 72/ 74 kDa 
glycoforms.  PGE2 was also measured in untreated cells and in cells treated with the non-substrate fatty 
acid, octanoic acid (OA).  As expected, PGE2 levels were extremely low in the untreated and OA-treated 
cell groups, and there were no significant differences between the two groups.   
 
3.3. Effect of AA on COX-2 glycoform expression 
 Although the presence of AA can lead to an increase in COX-2 by indirectly up-regulating its 
transcription [15,26], the mutant and wild-type COX-2 gene constructs used in this study were under the 
control of the pcDNA3 plasmid’s CMV promoter rather than their native COX-2 promoter.  Thus, the 
increased COX-2 activity in AA-treated cells (shown in Fig. 2) was not due to an increase in COX-2 
production.  However, to confirm that AA treatment had no effect on COX-2 protein synthesis, a Western 
blot was carried out on the same treatment groups described in Fig. 2.  Fig. 3 shows that AA-treated cells 
produced the same level of COX-2 protein as control cells (i.e. untreated and OA-treated cells). 
 
3.4. Conclusion 
A few past studies have examined the glycosylation of COX-2, but none succeeded in 
determining the significance or purpose of the two COX-2 glycoforms.  Though researchers found 
glycosylation of COX-2 at Asn53, Asn130, and Asn396 necessary for proper folding of COX-2 into an 
active, 72 kDa enzyme [23], no such function was found for the glycosylation site Asn580.  Ours is the 
first study to describe a biologically significant role for the glycosylation of Asn580 in the COX-2 protein.  
Additionally, our study introduces a new regulatory mechanism for COX-2 expression.  Regulation of 
COX-2 at the levels of transcription (reviewed in [27]) and post-transcription (i.e. mRNA stability) 
[28,29] has already been well-established.  In fact, we previously demonstrated that AA regulates COX-2 
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transcription via a feed-forward mechanism in prostate cancer [15,26], most likely mediated by the EP4 
prostaglandin receptor [30] and by activation of phosphatidylinositol 3-kinase (PI3K) [16].  However, 
regulation after protein synthesis appeared to be limited to the addition of exogenous COX-2 enzyme 
inhibitors (e.g. nonsteroidal anti-inflammatory drugs (NSAIDs)) [1].  As our study indicates, removal of 
glycosylation site Asn580 in the human COX-2 protein leads to an increase in total COX-2 activity (as 
reflected by a five-fold increase in PGE2) and an accumulation of both the 72 kDa and 70 kDa COX-2 
glycoforms.  Although the structure and activity level of the 70 kDa protein have yet to be determined, it 
is entirely possible that this glycoform contributed significantly to the overall increase in COX-2 activity 
found in the Asn580-mutant cells.  All these data suggest that normal turnover of COX-2 requires the 
conversion of the 72 kDa protein into the 74 kDa glycoform via glycosylation, indicating that regulation 
of COX-2 can also occur at the post-translational level.  This finding may be particularly important from a 
therapeutic perspective since increased levels of COX-2 protein have been implicated in various 
pathological conditions, and glycosylation of COX-2 appears to be involved with controlling those levels.  
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Fig. 1.  COX-2 glycoforms expressed from wild-type and mutant COX-2 genes.  A, Whole cell lysates 
were analyzed via Western blotting after transient transfection of COS-1 cells with either the wild-type or 
Asn580-mutant COX-2 gene.  Each lane was loaded with 15 µg of protein.  Blot shown represents a 
sample size of ten (n = 10).  Graph depicts densitometry values of COX-2 bands normalized to β-actin 
levels.  *** p<0.0001 compared to WT 72 kDa; n = 3.  B, Whole cell lysates were analyzed 3, 4, and 5 
days after transient transfection with the wild-type or mutant COX-2 gene.  Each lane was loaded with 15 
µg of protein.  Blot shown is representative of duplicate samples (n = 2).  Graphs depict densitometry 
values of COX-2 bands normalized to β-actin levels.  ANOVA p values: p=0.0116 for WT 74 kDa; 
p=0.0030 for WT 72 kDa; p=0.0049 for MUT 72 kDa; and p=0.0005 for MUT 70 kDa; n = 3 for 3-day 
data; n = 2 for 4- and 5-day data.  C, nontransfected control cells; WT, cells transfected with the wild-
type COX-2 gene; MUT, cells transfected with the mutant gene.  
 
Fig. 2.  Comparing activities of COX-2 glycoforms in the presence of arachidonic or octanoic acid.  Three 
days after transient transfection of COS-1 cells with either the wild-type (72/ 74 kDa) or mutant (70/ 72 
kDa) COX-2 gene, cells were treated with 5 µg/ml of arachidonic acid (AA) or octanoic acid (OA) for 2 
hours at 37°C.  Media was then analyzed for PGE2 using an ELISA.  Neg. Control, nontransfected cells.  
Data are represented as average ± SEM.  * p < 0.05 compared to other two “AA-treated” groups; ** p < 
0.001 compared to other two “72/ 74 kDa” groups; n = 3. 
 
Fig. 3.  Effect of arachidonic and octanoic acid on COX-2 protein expression.  Three days after transient 
transfection of COS-1 cells with either the wild-type (WT) or mutant (MUT) COX-2 gene, cells were 
treated with 5 µg/ml of arachidonic acid (AA) or octanoic acid (OA) for 2 hours at 37°C.  Whole cell 
lysates were then analyzed via Western blotting, each lane loaded with 10 µg of protein.  Blot shown is 
representative of triplicate samples (n = 3).  Graph depicts densitometry values of COX-2 bands 
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normalized to β-actin levels.  No statistically significant differences were found between nontreated (1), 
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